Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.60 |
| ▸ | MC3R | P41968 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.60 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.60 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27582932 | 0.88 | MAPK1 (0.56) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL9662759 | 0.80 | ADORA2B (0.61) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL5719318 | 0.79 | P2RX7 (0.60) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL5719031 | 0.79 | ADORA2B (0.54) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| Caffeine SCHEMBL10638955 | 0.77 | ADORA2B (0.73) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL5718827 | 0.77 | L3MBTL1 (0.58) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL8598384 | 0.77 | ADORA2B (0.51) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| Caffeine SCHEMBL28605141 | 0.76 | ADORA2B (0.71) | ADORA2BRXFP1SMN1; SMN2ADORA2APIK3CD | |
| SCHEMBL1944405 | 0.76 | ADORA2B (1.00) | ADORA2BRXFP1SMN1; SMN2POLBALDH1A1 | |
| Caffeine SCHEMBL8569482 | 0.75 | ADORA2B (1.00) | ADORA2BADORA2APIK3CDPOLBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0322206-A2 | Compositions and methods for improving cold tolerance in animals and humans | HER MAJESTY IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 1989-06-28 | — | — | EP | claimed |
| US-12595269-B2 | Morpholine-like monoamine releasers | Solvonis Therapeutics Ireland Holdings Limited (IE) | 2026-04-07 | — | — | US | disclosed |
| US-12590077-B2 | Short-acting monoamine releasers | Solvonics Therapeutics Ireland Holdings Limited (IE) | 2026-03-31 | — | — | US | disclosed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-06-05 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-03-27 | — | — | US | disclosed |
| EP-4479404-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | Awakn Ls Europe Holdings Limited (IE) | 2024-12-25 | — | — | EP | disclosed |
| US-6413558-B1 | MIXTURE OF MONOSACCHARIDES, DISACCHARIDES AND MALTODEXTRIN | THE PROCTOR & GAMBLE CO. | 2002-07-02 | — | — | US | disclosed |
| EP-1196050-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2002026055-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND DEFINED VITAMINS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026053-A2 | BEVERAGE COMPOSITIONS COMPRISING ARABINOGALACTAN AND MINERAL SUPPLEMENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093831-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093832-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED DOSAGE REQUIREMENTS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093833-A2 | KITS AND METHODS FOR OPTIMIZING THE EFFICACY OF CHONDROPROTECTIVE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093701-A2 | AQUEOUS CHONDROPROTECTIVE COMPOSITIONS HAVING DEFINED PH LIMITATIONS FOR EFFICACIOUS DELIVERY | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | DBH, TSPO, DDO | ADORA2B 1230/4885RXFP1 2481/4885SMN1; SMN2 580/4885 |
| US-12590077-B2 | Short-acting monoamine releasers | SLC6A2, NPY2R, SLC6A3 | ADORA2B 747/4885RXFP1 2382/4885SMN1; SMN2 245/4885 |
| US-12595269-B2 | Morpholine-like monoamine releasers | HTR3B, HTR3D, SLC6A3 | ADORA2B 663/4885RXFP1 613/4885SMN1; SMN2 609/4885 |
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | ADORA2B 1369/4885RXFP1 816/4885SMN1; SMN2 1542/4885 |
| US-20250179089-A1 | BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS | PNMT, SLC18A2, HTR2C | ADORA2B 494/4885RXFP1 2492/4885SMN1; SMN2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.